Amy Lauren Cummings

Title(s)HS Assistant Clinical Professor, Medicine
SchoolMedicine
ORCID ORCID Icon0000-0003-0472-392X Additional info
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Consent document translation expense hinders inclusive clinical trial enrolment. Nature. 2023 Aug; 620(7975):855-862. Velez MA, Glenn BA, Garcia-Jimenez M, Cummings AL, Lisberg A, Nañez A, Radwan Y, Lind-Lebuffe JP, Brodrick PM, Li DY, Fernandez-Turizo MJ, Gower A, Lindenbaum M, Hegde M, Brook J, Grogan T, Elashoff D, Teitell MA, Garon EB. PMID: 37532930.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives. J Thorac Oncol. 2023 11; 18(11):1458-1477. Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam C, Chaft JE. PMID: 37451404.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    3. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. PMID: 37068173.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    4. Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. JTO Clin Res Rep. 2023 Mar; 4(3):100468. Smith CP, Xiang M, Yoon SM, Lee A, Ruan D, Goldman JW, Cummings AL, Lisberg A, Garon EB, Moghanaki D. PMID: 36923158; PMCID: PMC10009282.
      View in: PubMed   Mentions: 1  
    5. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Dec; 3(12):100427. Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. PMID: 36426286; PMCID: PMC9679033.
      View in: PubMed   Mentions: 5  
    6. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. Cancer Immunol Immunother. 2023 Feb; 72(2):339-350. Gao Y, Stein MM, Kase M, Cummings AL, Bharanikumar R, Lau D, Garon EB, Patel SP. PMID: 35881197; PMCID: PMC9870967.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    7. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer. 2021 11; 161:34-41. Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. PMID: 34507111; PMCID: PMC8923054.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2021 08 15; 27(16):4566-4573. Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. PMID: 34108179.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    9. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. Nat Cancer. 2020 12; 1(12):1167-1175. Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bachrach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. PMID: 35121931.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    10. Targeted Therapy for Non-Small Cell Lung Cancer. Semin Respir Crit Care Med. 2020 Jun; 41(3):409-434. Noor ZS, Cummings AL, Johnson MM, Spiegel ML, Goldman JW. PMID: 32450595.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    11. KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S403-S406. Cummings AL, Garon EB. PMID: 32038925; PMCID: PMC6987348.
      View in: PubMed   Mentions: 2  
    12. KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. Transl Lung Cancer Res. 2019 Oct; 8(5):706-709. Cummings AL, Santoso KM, Goldman JW. PMID: 31737507; PMCID: PMC6835110.
      View in: PubMed   Mentions: 4  
    13. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840; PMCID: PMC6901027.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    14. Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. JCO Clin Cancer Inform. 2018 12; 2:1-12. Fares CM, Williamson TJ, Theisen MK, Cummings A, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. PMID: 30652613; PMCID: PMC6724714.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018 08; 13(8):1138-1145. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. PMID: 29874546; PMCID: PMC6063769.
      View in: PubMed   Mentions: 237     Fields:    Translation:HumansCTClinical Trials
    16. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018; 12:209-215. Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A. PMID: 29416316; PMCID: PMC5789049.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    17. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med. 2017 Nov; 14(4):341-347. Cummings AL, Garon EB. PMID: 29372100; PMCID: PMC5785166.
      View in: PubMed   Mentions: 2     Fields:    
    18. Thyroid carcinoma metastases to axillary lymph nodes: report of two rare cases of papillary and medullary thyroid carcinoma and literature review. Endocr Pract. 2014 Mar; 20(3):e34-7. Cummings AL, Goldfarb M. PMID: 24246352.
      View in: PubMed   Mentions: 6     Fields:    
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Amy's Networks
    Concepts (61)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (30)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California